Lv1
80 积分 2024-12-31 加入
Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a meta-analysis
3个月前
已完结
Safety and efficacy of inclisiran in treating hypercholesterolemia: a systemic review and meta-analysis
3个月前
已完结
Long-Term Cognitive Safety of Achieving Very Low LDL Cholesterol with Evolocumab
3个月前
已完结
Adjunctive PCSK9 Inhibitor Evolocumab in the Prevention of Early Neurological Deterioration in Non-cardiogenic Acute Ischemic Stroke: A Multicenter, Prospective, Randomized, Open-Label, Clinical Trial
3个月前
已完结
Efficacy and safety of PCSK9 inhibitors in real life
3个月前
已关闭
Lerodalcibep and evolocumab for the treatment of homozygous familial hypercholesterolaemia with PCSK9 inhibition (LIBerate-HoFH): a phase 3, randomised, open-label, crossover, non-inferiority trial
3个月前
已完结
Evolocumab for the reduction of cardiovascular risk in HIV patients: is this a clinician’s best option for HIV patients?
3个月前
已完结
Long-Term Lipid Lowering With Evolocumab in Older Individuals
3个月前
已完结
Efficacy and safety of ongericimab in Chinese patients with heterozygous familial hypercholesterolemia: a randomized, double-blind, placebo-controlled phase 3 trial
3个月前
已完结
Comprehensive evaluation of siRNA therapeutics on Lp(a): A network meta‐analysis
3个月前
已完结
皖公网安备34019202002308
